How Do Chronic Disorders Impacts Cell Culture Media?

Published On: October 2022

Cell Culture Media Article Insights:

The need for cell culture media to accurately diagnose infectious microorganisms has increased due to the number of reported contagious diseases. The market has gained momentum because of the growing financing for cell-based research. The study on the global cell culture media market comprehensively evaluates the market.

To control and support the development of cells or microorganisms employed in biopharmaceuticals, a cell culture medium is often a gel or liquid. The fastest-growing subset of the cell culture industry, the culture medium is a crucial component in the production of biopharmaceuticals since it promotes cell development. The quick expansion is mainly caused by the rising demand for biopharmaceuticals, supportive governmental regulations, and rising R&D expenditures.

The research thoroughly analyzes the market's key segments, trends, drivers, restraints, competitive environment, and other essential elements.

The global cell culture media market size was estimated at USD 3,616.8 million in 2021 and is anticipated to increase at a CAGR of 12.1% from 2022 to 2030.

Over the past few decades, the cell culture media market has advanced more than ever. One of the most dependable, robust, and developed technologies is thought to be used to create biotherapeutic goods. There are several uses of cell culture, including using cells as model systems in cancer research, virology, toxicity testing, vaccine development, and gene therapy. Because diabetes, immunological disorders, and other illnesses are becoming more common, cell cultures are used in genetic engineering to create proteins like insulin, monoclonal antibodies, and hormones.

Traditional media, serum-containing media, and serum-free media are in higher demand due to the widespread use of cell culture in many healthcare applications and the scale of its manufacturing.  Furthermore, clinical studies have risen, creating more lucrative prospects throughout the review. For example, the overall number of industry-sponsored trials for regenerative medicine increased by 100 from 2020 to 2021, totaling 1,320. Around the world, regenerative medicine trials totaling 1,328 were funded by non-industry organizations such as government agencies and academic institutions.

The market for biosimilars is poised for significant expansion. As the patents on essential medications like trastuzumab (Herceptin from Roche), infliximab (Remicade from J&J), and adalimumab (Humira from Abbott) are about to expire, additional mAb biosimilars are expected to be introduced in the coming years. Additionally, there is more significant potential for biosimilar monoclonal antibodies because of the extension of regulated approval pathways for biosimilars in developing markets.

In 2021, North America dominated the market and contributed 38.1% of total sales. This significant percentage can be linked to the expansion of the biotechnology and pharmaceutical sectors, the increasing number of approved vaccines on cell culture, the rising prevalence of diseases like cancer, and the investments and funding made in cell-based research.

Since more people are becoming aware of the cell culture technique's usage, the Asia-Pacific market is predicted to expand quickly. In addition, deliberate moves by significant firms to increase their market share in the Asia-Pacific region are anticipated to present profitable prospects. For instance, Fujifilm Irvine Scientific, Inc. began building its new bioprocessing facility in China in December 2021 to support cell culture media optimization for developing biotherapeutic drugs, vaccines, and advanced therapies.

Significant players in this sector use various techniques to increase their market position, such as partnerships through mergers and acquisitions, geographic growth, and strategic collaborations. For instance, in July 2021, Sartorius purchased Xell AG, a leader in cell culture, through its subsidiary Sartorius Stedim Biotech. The business creates, manufactures, and sells feed additives and media for cell cultures, primarily to produce viral vectors used in vaccine and gene therapy production.

The COVID-19 pandemic outbreak has increased demand for tried-and-true cell-based vaccine manufacturing technology. Additionally, it has sparked a few scientific breakthroughs, especially in developing and testing vaccination technologies. For instance, the Vero cell line, which was derived from the kidney of an African green monkey, has been widely applied to the production of viral vaccines. Additionally, it has been utilized to create several SARS-CoV subtypes. Lonza Bioscience's ProVeroTM1 Serum-free Medium is a protein-free, non-animal origin medium created to assist the development of Vero cells and MDCK.